The US Food and Drug Administration has approved AbbVie’s treatment for Parkinson’s disease in adults.
The drug, tavapadon, was acquired by AbbVie through its $8.7 billion purchase of Cerevel Therapeutics in 2023. It will be sold under the brand name Juvmo.
Juvmo is a once-a-day pill for patients with Parkinson’s disease, a long-term brain disorder that gradually affects movement control and can cause tremors, stiffness and balance problems.
AbbVie said more than 11 million people worldwide live with the disease.
The drug works by mimicking dopamine, a vital brain chemical that naturally declines in people with Parkinson’s disease.
The FDA’s approval was based on data from AbbVie’s late-stage trial programme, which showed the medicine improved symptoms in patients.
Common side effects reported in the trials included nausea, dizziness and headache.
AbbVie did not immediately comment on the drug’s launch or pricing. Citi analysts had previously said the launch was expected in the third quarter of 2026, with uptake likely to be gradual as Medicare coverage negotiations continue.
The post US FDA Approves New Parkinson’s Drug appeared first on ProPakistani.